Novartis | NOVN - Gewinn Vor Steuern

Aktienkurs
121.40
Täglich Wechseln
0.22 0.18%
Monatlich
-0.49%
Jährlich
43.31%
Q2 Prognose
120.10




Gewinn Vor Steuern Veränderung Datum
AbbVie USD 4.38B 1.92B 2025-09
Alcon AG USD 264M 19M 2025-12
Almirall EUR 30.32M 22M 2025-12
Amgen USD 3.92B 2.35B 2025-09
AstraZeneca USD 3.24B 117M 2025-09
Autolus Therapeutics Ltd USD -91.52M 12.93M 2025-12
Bayer EUR -1.16B 735M 2025-09
Biogen USD 557.3M 186.7M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Eli Lilly USD 7.23B 456M 2025-09
Fresenius EUR 601M 122M 2025-12
Fresenius Medical Care EUR 508.46M 105.89M 2025-12
Galapagos EUR -221.49M 117.07M 2025-09
Genmab DKK 55M 427M 2025-12
Gilead Sciences USD 3.64B 1.21B 2025-09
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
GRIFOLS EUR 190.51M 20.03M 2025-06
Hikma Pharmaceutical USD 147.5M 3.5M 2025-06
J&J USD 4.97B 2.53B 2025-12
Lonza CHF 624M 197M 2024-12
Merck EUR 1.29B 458.1M 2025-09
Merck USD 6.74B 22M 2025-09
Novartis USD 4.64B 445M 2025-12
Novartis USD 5.17B 637M 2025-09
Novo Nordisk DKK 33.8B 3.23B 2025-06
Orion EUR 327M 206.6M 2025-12
Pfizer USD 3.33B 290M 2025-09
Philips EUR 275M 62M 2025-09
Recordati EUR 144.95M 25.46M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
UCB EUR 789M 427M 2025-06